Norelgestromin/ethinylestradiol
Combination of | |
---|---|
Norelgestromin | Progestogen |
Ethinylestradiol | Estrogen |
Names | |
Trade names | Ortho Evra, Xulane, Evra |
IUPAC name
| |
Clinical data | |
WHO AWaRe | UnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽ |
Pregnancy category |
|
Routes of use | Transdermal (patch) |
External links | |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a602006 |
Legal | |
License data | |
Legal status | |
Identifiers | |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ATC code | |
Chemical and physical data | |
Formula | C41H53NO4 |
Molar mass | 623.878 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Norelgestromin/ethinylestradiol, sold under the brand name Ortho Evra among others, is a contraceptive patch containing the progestin norelgestromin and the estrogen ethinylestradiol.[3][4] As of December 2016, the product Ortho Evra has been discontinued in the U.S. while the product Xulane continues to be marketed.[5][3][6]
The most common side effects include headache, nausea (feeling sick), breast tenderness, and irregular uterine bleeding.[4][3]
Norelgestromin/ethinylestradiol was approved for medical use in the United States in November 2001, and in the European Union in August 2002.[7][4]
Norelgestromin/ethinylestradiol is a transdermal patch (a patch that delivers a medicine across the skin).[4] For the first three weeks of the menstrual cycle a new patch should be applied every week, followed by a fourth week, which is patch-free.[4] The patch-free interval must not be longer than seven days; otherwise, additional non-hormonal contraceptive methods must be used, such as condoms.[4] Transdermal patches must always be applied on the same day of the week to the buttock, abdomen (belly), upper arm or upper back.[4] The same area of skin should not be used for two consecutive patches.[4] Norelgestromin/ethinylestradiol may work less well in women weighing 198 pounds (90 kg) or more.[4]
Medical uses
In the United States norelgestromin/ethinylestradiol is indicated for the prevention of pregnancy in women with a BMI < 30 kg/m2 for whom a transdermal delivery system is an appropriate method of contraception.[3]
In the European Union, norelgestromin/ethinylestradiol is indicated for use as female contraception.[4]
Society and culture
Cost
The cost in the U.S. of this medication is $46 (USD) for 1 transdermal extended release film 35 mcg-150 mcg/24 hr[8]
- Norelgestromin/ethinylestradiol costs (US)
- Norelgestromin/ethinylestradiol prescriptions (US)
See also
References
- ↑ "Evra Product information". Health Canada. 21 June 2018. Archived from the original on 18 February 2020. Retrieved 17 February 2020.
- ↑ "Evra transdermal patch - Summary of Product Characteristics (SmPC)". (emc). 26 June 2020. Archived from the original on 24 October 2020. Retrieved 4 July 2020.
- 1 2 3 4 "Xulane- norelgestromin and ethinyl estradiol patch". DailyMed. 7 April 2020. Archived from the original on 6 July 2020. Retrieved 4 July 2020.
- 1 2 3 4 5 6 7 8 9 10 "Evra EPAR". European Medicines Agency (EMA). Archived from the original on 12 November 2020. Retrieved 4 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Ortho Evra (norelgestromin/ethinyl estradiol transdermal system) Initial U.S. Approval: 2001". DailyMed. 12 July 2018. Archived from the original on 5 July 2020. Retrieved 4 July 2020.
- ↑ "Ortho Evra: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 5 July 2020. Retrieved 4 July 2020.
- ↑ "Drug Approval Package: Ortho EVRA (Norelgestromin/Ethinyl Estradiol Transdermal System NDA #21-180". U.S. Food and Drug Administration (FDA). Archived from the original on 5 July 2020. Retrieved 4 July 2020.
- ↑ "Ortho Evra Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 7 September 2015. Retrieved 30 March 2021.
External links
- "Ethinyl Estradiol mixture with norelgestromin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 9 February 2021. Retrieved 19 January 2021.